<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="121031">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01918371</url>
  </required_header>
  <id_info>
    <org_study_id>GMA-OZU-13-598</org_study_id>
    <nct_id>NCT01918371</nct_id>
  </id_info>
  <brief_title>A Retrospective Study of Anti-Vascular Endothelial Growth Factor (VEGF) Injections for Retinal Vein Occlusion or Diabetic Macular Edema</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This retrospective data review study will evaluate anti-VEGF injections for retinal vein
      occlusion (RVO) or diabetic macular edema (DME).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Retrospective</study_design>
  <primary_outcome>
    <measure>Percentage of Patients with Best Corrected Visual Acuity (BCVA) of 20/40 or Better and Central Retinal Thickness (CRT) ≤250 µm on Time Domain (TD) Optical Coherence Tomography (OCT) or ≤300 µm on Spectral Domain (SD) OCT in the Study Eye</measure>
    <time_frame>4 Years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients with BCVA of 20/40 or Better in the Study Eye</measure>
    <time_frame>4 Years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients with CTR of ≤250 µm on TD OCT or ≤300 µm on SD OCT in the Study Eye</measure>
    <time_frame>4 Years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients with Both BCVA 20/40 or Better or CTR ≤250 µm on TD OCT or ≤300 µm on SD OCT in the Study Eye</measure>
    <time_frame>4 Years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients with BCVA 20/40 or Worse or CRT ≥250 µm on TD OCT or ≥300 µm on SD OCT AND, Compared with the Visit 3 Months Before the Current Visit, Patient had a Gain of &lt;1 Line in BCVA or a Decrease of &lt;50 µm in CRT in the Study Eye</measure>
    <time_frame>4 Years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean BCVA in the Study Eye</measure>
    <time_frame>4 Years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in BCVA in the Study Eye</measure>
    <time_frame>Baseline, 4 Years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients with an Increase from Baseline of ≥2 Lines in BCVA in the Study Eye</measure>
    <time_frame>Baseline, 4 Years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients with an Increase from Baseline of ≥3 Lines in BCVA in the Study Eye</measure>
    <time_frame>Baseline, 4 Years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in CRT in the Study Eye</measure>
    <time_frame>Baseline, 4 Years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Improvement of ≥2 Lines in BCVA in the Study Eye</measure>
    <time_frame>4 Years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Improvement of ≥3 Lines in BCVA in the Study Eye</measure>
    <time_frame>4 Years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Improvement in BCVA to 20/40 or Better in the Study Eye</measure>
    <time_frame>4 Years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Improvement in CRT of ≤250 µm on TD OCT or ≤300 µm on SD OCT in the Study Eye</measure>
    <time_frame>4 Years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Improvement to Both 20/40 or Better in BCVA and Improvement in CRT of ≤250 µm on TD OCT or ≤300 µm on SD OCT in the Study Eye</measure>
    <time_frame>4 Years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time Between Anti-VEGF Injections in the Study Eye</measure>
    <time_frame>4 Years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Anti-VEGF Injections in the Study Eye</measure>
    <time_frame>4 Years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in BCVA Following the Last Anti-VEGF Injection in the Study Eye</measure>
    <time_frame>Baseline, 12 Weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients switching to a 2nd or 3rd Anti-VEGF After the First Injection in the Study Eye</measure>
    <time_frame>4 Years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Switching Among Different Anti-VEGFs in the Study Eye</measure>
    <time_frame>4 Years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients with Focal Laser in the Study Eye</measure>
    <time_frame>4 Years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients with Panretinal Photocoagulation (PRP) in the Study Eye</measure>
    <time_frame>4 Years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Using Corticosteroids in the Study Eye</measure>
    <time_frame>4 Years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients with a Loss, Gain and No Change from Baseline in BCVA by ≥1 Line in the Study Eye</measure>
    <time_frame>Baseline, 4 Years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients with Glaucoma Laser Surgery in the Study Eye</measure>
    <time_frame>4 Years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients with Incisional Glaucoma Surgery in the Study Eye</measure>
    <time_frame>4 Years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Phakic Patients with Cataract Surgery in the Study Eye</measure>
    <time_frame>4 Years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Retinal Vein Occlusion</condition>
  <condition>Macular Edema</condition>
  <arm_group>
    <arm_group_label>Patients with Retinal Vein Occlusion or Diabetic Macular Edema</arm_group_label>
    <description>Patients with retinal vein occlusion or diabetic macular edema receiving anti-VEGF injection(s) in accordance with standard of care practices. This is a retrospective chart review study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-VEGF</intervention_name>
    <description>Patients with retinal vein occlusion or diabetic macular edema receiving anti-VEGF injection(s) in accordance with standard of care practices. This is a retrospective chart review study.</description>
    <arm_group_label>Patients with Retinal Vein Occlusion or Diabetic Macular Edema</arm_group_label>
    <other_name>Avastin®</other_name>
    <other_name>Lucentis®</other_name>
    <other_name>Eylea®</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Received Anti-VEGF injections for retinal vein occlusion (RVO) or diabetic macular edema
        (DME)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Macular edema in the study eye due to RVO or DME

          -  Received an anti-VEGF injection in the study eye on or after June 2010 for RVO and on
             or after August 2012 for DME

        Exclusion Criteria:

          -  None
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Allergan Inc.</last_name>
    <email>clinicaltrials@allergan.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 23, 2014</lastchanged_date>
  <firstreceived_date>August 5, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Retinal Vein Occlusion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Endothelial Growth Factors</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
